Back to top

gene-editing: Archive

Zacks Equity Research

CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss

CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.

VRTXPositive Net Change UTHRNegative Net Change LGNDNegative Net Change CRSPNegative Net Change

Zacks Equity Research

Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil

Rocket Pharmaceuticals' (RCKT) first-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.

UTHRNegative Net Change LGNDNegative Net Change ANIPNegative Net Change RCKTNegative Net Change

Zacks Equity Research

Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?

Vertex's (VRTX) revenues in the first quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.

ALNYPositive Net Change VRTXPositive Net Change CRSPNegative Net Change ALPNNegative Net Change